Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FARIA AMJAD

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1518285204
CMS profile
1373417
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$93,150.56

179 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FARIA AMJAD

NPI 1518285204 · CMS profile ID 1373417

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518285204?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FARIA AMJAD, NPI 1518285204, CMS profile ID 1373417. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518285204?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). FARIA AMJAD, NPI 1518285204, CMS profile ID 1373417. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518285204?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
FARIA AMJAD, NPI 1518285204, CMS profile ID 1373417, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1518285204?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

179 matching records · $93,150.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 179 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 179.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $46.1411/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914765043 CMS
Alexion Pharmaceuticals, Inc. $237.6311/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914824805 CMS
Celgene Corporation $24.6411/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565235 CMS
E.R. Squibb & Sons, L.L.C. $41.7911/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565247 CMS
E.R. Squibb & Sons, L.L.C. $964.7511/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565251 CMS
E.R. Squibb & Sons, L.L.C. $622.6311/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565261 CMS
E.R. Squibb & Sons, L.L.C. $467.4011/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565269 CMS
E.R. Squibb & Sons, L.L.C. $1,952.8310/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565291 CMS
E.R. Squibb & Sons, L.L.C. $29.1910/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565299 CMS
E.R. Squibb & Sons, L.L.C. $680.9610/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565309 CMS
Merz Pharmaceuticals, LLC $24.9910/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943790115 CMS
Novartis Pharmaceuticals Corporation $24.7610/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500149 CMS
ACADIA Pharmaceuticals Inc $24.1210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952372017 CMS
Alexion Pharmaceuticals, Inc. $22.7610/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914710683 CMS
E.R. Squibb & Sons, L.L.C. $3,120.0010/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565173 CMS
Celgene Corporation $6.0110/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565121 CMS
Celgene Corporation $22.3410/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565127 CMS
Novartis Pharmaceuticals Corporation $4.4210/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500145 CMS
Genentech USA, Inc. $121.9810/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950740707 CMS
Horizon Therapeutics plc $3.3609/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937586237 CMS
GENZYME CORPORATION $26.0609/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939029059 CMS
E.R. Squibb & Sons, L.L.C. $590.2409/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565169 CMS
Biogen, Inc. $14.6809/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923463787 CMS
Amneal Pharmaceuticals LLC $30.4509/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956572877 CMS
Acorda Therapeutics, Inc $12.9909/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920333911 CMS
Biogen, Inc. $27.1209/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923414211 CMS
Novartis Pharmaceuticals Corporation $6.9209/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500143 CMS
Horizon Therapeutics plc $14.3009/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937586235 CMS
Biogen, Inc. $27.4608/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923415521 CMS
Biogen, Inc. $4,008.0008/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923416873 CMS
Celgene Corporation $14.9008/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565077 CMS
Horizon Therapeutics plc $51.5008/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937586233 CMS
Genentech USA, Inc. $24.2008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950695045 CMS
Ipsen Biopharmaceuticals, Inc $62.4908/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893398225 CMS
Biogen, Inc. $19.8608/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923439631 CMS
Horizon Therapeutics plc $46.1808/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937586231 CMS
GENZYME CORPORATION $45.1308/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939029045 CMS
Novartis Pharmaceuticals Corporation $24.9208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500141 CMS
Biogen, Inc. $16.1607/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923465045 CMS
Biogen, Inc. $3,256.5007/19/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923438245 CMS
Novartis Pharmaceuticals Corporation $3,650.0007/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500119 CMS
Alexion Pharmaceuticals, Inc. $16.5807/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915124985 CMS
Biogen, Inc. $30.8107/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923400809 CMS
Horizon Therapeutics plc $7.0307/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937586229 CMS
Novartis Pharmaceuticals Corporation $6.4407/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893500139 CMS
Biogen, Inc. $18.5507/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923426321 CMS
Ipsen Biopharmaceuticals, Inc $20.1606/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893395717 CMS
GENZYME CORPORATION $58.4906/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939028903 CMS
Celgene Corporation $16.2106/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932565027 CMS
Alexion Pharmaceuticals, Inc. $1,029.0006/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914696725 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $99,351.24 163
PY2020 $65,187.21 89
PY2021 $57,492.07 105
PY2022 $93,150.56 179
PY2023 $66,125.20 212
PY2024 $64,289.59 171
PY2025 $111,449.95 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,514.62 2
PY2025 Principal investigator $942,927.17 89
PY2024 Principal investigator $898,011.78 45
PY2023 Principal investigator $607,968.89 45
PY2022 Principal investigator $326,435.72 34
PY2021 Principal investigator $166,597.41 13
PY2020 Principal investigator $216,730.39 52
PY2019 Principal investigator $263,658.75 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $4,590.30 12/09/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198237
Principal investigator 1 TG Therapeutics, Inc. $800.58 12/08/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198233
Principal investigator 1 Genentech, Inc. $9,770.00 12/05/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
OCARINA I No dispute reported 06/30/2026 1211610486
Principal investigator 1 Genentech, Inc. $13,827.00 12/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610482
Principal investigator 1 TG Therapeutics, Inc. $1,920.00 12/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198241
Principal investigator 1 TG Therapeutics, Inc. $3,440.00 12/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198243
Principal investigator 1 TG Therapeutics, Inc. $2,500.00 12/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198245
Principal investigator 1 Genentech, Inc. $2,475.00 11/20/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
OCARINA I No dispute reported 06/30/2026 1211610478
Principal investigator 1 Novartis Pharmaceuticals Corporation $333.00 11/18/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190295123
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,611.15 11/12/2025 Non-covered Recipient Entity
Georgetown University
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1235997159
Principal investigator 1 GENZYME CORPORATION $18,740.00 11/04/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141614
Principal investigator 1 Novartis Pharmaceuticals Corporation $559.00 11/01/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190297473
Principal investigator 1 TG Therapeutics, Inc. $2,295.15 11/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198235
Principal investigator 1 TG Therapeutics, Inc. $14,090.00 11/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198239
Principal investigator 1 Genentech, Inc. $4,950.00 10/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
OCARINA I No dispute reported 06/30/2026 1211610471
Principal investigator 1 Genentech, Inc. $4,342.00 10/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610475
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,092.76 10/21/2025 Non-covered Recipient Entity
MEDSTAR HEALTH
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190302141
Principal investigator 1 Genentech, Inc. $2,612.00 10/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610631
Principal investigator 1 GENZYME CORPORATION $13,646.90 10/10/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226140158
Principal investigator 1 Novartis Pharmaceuticals Corporation $102.00 10/09/2025 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190303523
Principal investigator 1 Novartis Pharmaceuticals Corporation $131.29 10/08/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190297470
Recipient F. Hoffmann-La Roche AG $424.06 10/03/2025 Covered Recipient Physician Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial No dispute reported 06/30/2026 1211535746
Recipient F. Hoffmann-La Roche AG $1,090.56 10/02/2025 Covered Recipient Physician Efficacy Tolerability of Ocrelizumab in African Americans Hispanic Americans vs Caucasians No dispute reported 06/30/2026 1211535751
Principal investigator 1 Novartis Pharmaceuticals Corporation $60.00 10/01/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190297477
Principal investigator 1 TG Therapeutics, Inc. $15,359.93 09/30/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198225
Principal investigator 1 TG Therapeutics, Inc. $1,900.00 09/25/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198229
Principal investigator 1 Genentech, Inc. $2,210.00 09/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610604
Principal investigator 1 Genentech, Inc. $6,255.00 09/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211610790
Principal investigator 1 Genentech, Inc. $42,685.00 09/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610466
Principal investigator 1 GENZYME CORPORATION $4,000.00 09/10/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226140154
Principal investigator 1 GENZYME CORPORATION $3,500.00 09/05/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226140141
Principal investigator 1 GENZYME CORPORATION $12,654.16 09/03/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141588
Principal investigator 1 Novartis Pharmaceuticals Corporation $473.31 09/01/2025 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190301777
Principal investigator 1 TG Therapeutics, Inc. $6,376.81 08/31/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198223
Principal investigator 1 GENZYME CORPORATION $22,700.00 08/28/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226140146
Principal investigator 1 GENZYME CORPORATION $18,050.00 08/28/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226140150
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 08/28/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198231
Principal investigator 1 Genentech, Inc. $5,551.00 08/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610461
Principal investigator 1 GENZYME CORPORATION $3,500.00 08/25/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141584
Principal investigator 1 GENZYME CORPORATION $12,647.50 08/04/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141560
Principal investigator 1 TG Therapeutics, Inc. $5,800.00 08/04/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198221
Principal investigator 1 Genentech, Inc. $2,050.00 07/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211610793
Principal investigator 1 Genentech, Inc. $12,204.00 07/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610457
Principal investigator 1 Genentech, Inc. $11,864.00 07/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610554
Principal investigator 1 TG Therapeutics, Inc. $3,460.00 07/15/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198227
Principal investigator 1 Hoffmann-La Roche Limited $5,525.00 07/11/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211610063
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,258.51 07/08/2025 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190300567
Principal investigator 1 Genentech, Inc. $35,573.00 07/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211610797
Principal investigator 1 Roche Products Limited $90.00 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610329
Principal investigator 1 Roche Products Limited $1,838.70 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610332
Principal investigator 1 Celgene Corporation $5,750.00 06/25/2025 Non-covered Recipient Entity
Georgetown University
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306571
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610304
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610308
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610312
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610316
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610320
Principal investigator 1 Roche Products Limited $371.00 06/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610325
Principal investigator 1 Genentech, Inc. $22,917.60 06/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211610782
Principal investigator 1 Genentech, Inc. $2,479.00 06/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211610786
Principal investigator 1 TG Therapeutics, Inc. $5,800.00 06/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198217
Principal investigator 1 TG Therapeutics, Inc. $3,295.00 05/29/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198215
Principal investigator 1 Genentech, Inc. $10,581.00 05/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610450
Principal investigator 1 Genentech, Inc. $8,451.00 04/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
OCARINA I No dispute reported 06/30/2026 1211610445
Principal investigator 1 Genentech, Inc. $68.00 04/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610540
Principal investigator 1 Genentech, Inc. $2,527.00 04/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610518
Principal investigator 1 Genentech, Inc. $7,600.00 04/14/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
OCARINA I No dispute reported 06/30/2026 1211610453
Principal investigator 1 GENZYME CORPORATION $5,997.98 04/07/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141525
Principal investigator 1 GENZYME CORPORATION $2,535.00 04/02/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141510
Principal investigator 1 GENZYME CORPORATION $31,800.00 04/02/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141513
Principal investigator 1 Genentech, Inc. $13,620.00 04/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610536
Principal investigator 1 TG Therapeutics, Inc. $6,400.00 03/31/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198205
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 03/24/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198219
Principal investigator 1 TG Therapeutics, Inc. $700.00 03/21/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198213
Principal investigator 1 TG Therapeutics, Inc. $8,260.00 03/19/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198211
Principal investigator 1 TG Therapeutics, Inc. $2,500.00 02/27/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198207
Principal investigator 1 TG Therapeutics, Inc. $700.00 02/27/2025 Non-covered Recipient Entity
Georgetown University Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198209
Principal investigator 1 GENZYME CORPORATION $51,405.46 02/24/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141498
Principal investigator 1 Genentech, Inc. $10,307.00 02/14/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211610442
Principal investigator 1 GENZYME CORPORATION $1,135.00 02/04/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141482
Principal investigator 1 GENZYME CORPORATION $15,250.00 02/04/2025 Non-covered Recipient Entity
Georgetown University Office Of Tech Commercialization
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141489
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,397.81 01/31/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190295117
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,935.56 01/28/2025 Non-covered Recipient Entity
PRESIDENT DIRECTORS OF GEORGE COLLEGE FOR GEORGETOWN UNIVERSITY LOMBARDI COMPREHENSIVE CANCER C
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190298626
Principal investigator 1 Genentech, Inc. $2,812.00 01/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211610502
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610280
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610284
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610288
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610292
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610295
Principal investigator 1 Roche Products Limited $371.00 01/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211610299
Principal investigator 1 Novartis Pharmaceuticals Corporation $263,319.51 01/02/2025 Non-covered Recipient Entity
MEDSTAR HEALTH
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190302143
Principal investigator 1 Novartis Pharmaceuticals Corporation $180.00 01/01/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190295129